Clinical efficacy and safety outcomes of anlotinib therapy in sarcoma: a systematic review and meta-analysis
Hasan Matar, Ahmad Melhem, Abdallah Shawwa, Taleen Yousef, Mohammad Alananbeh, Enad Alsalim, Eman Al-refai, Malaak Abuhwaij, Dina Elayan · 2026
Read Clinical efficacy and safety outcomes of anlotinib therapy in sarcoma: a systematic review and meta-analysis by Hasan Matar, Ahmad Melhem, Abdallah Shawwa, Taleen Yousef, Mohammad Alananbeh, Enad Alsalim, Eman Al-refai, Malaak Abuhwaij, Dina Elayan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13400519.txt.
Description
Hasan Matar and colleagues pool, in 2026, the evidence on anlotinib, an oral drug that blocks blood vessel growth signals, for sarcoma. Sarcomas are rare cancers of connective tissues, and advanced cases still do poorly. Anlotinib had shown early promise across solid tumors, prompting a formal summary.
Searching five databases to February 2025, the team found 21 studies covering 1,230 patients with advanced or spreading sarcoma. Pooled results gave a median time without growth of under seven months and median survival of about nineteen months. Effects varied by sarcoma type, stage and prior treatment, yet most studies showed real tumor control with manageable side effects. Larger trials with marker guidance are still needed.
Catalog record
| CREATOR | Hasan Matar, Ahmad Melhem, Abdallah Shawwa, Taleen Yousef, Mohammad Alananbeh, Enad Alsalim, Eman Al-refai, Malaak Abuhwaij, Dina Elayan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38686 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |